Stockreport

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Prof...

Allakos Inc.  (ALLK) 
Last allakos inc. earnings: 11/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
PDF – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., Jun [Read more]